Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591755 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
A Phase 3 study of Seasonal Allergic Conjunctivitis, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 229
- Enrollment target
- 6
- Study locations
NCT05591755 is a Phase 3 study of Seasonal Allergic Conjunctivitis that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 229 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT05591755, a Phase 3 study of Seasonal Allergic Conjunctivitis, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 229 participants
- Enrollment target
- 6
- Study locations
Study Summary
To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.
Conditions Studied
Interventions
- DRUG Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
- DRUG Ketotifen fumarate ophthalmic solution 0.035%
- DRUG Brimonidine tartrate ophthalmic solution 0.025%
- DRUG Experimental: Vehicle ophthalmic solution
Study Locations (6)
Tennessee
- 105 - Advancing Vision Research - Goodlettsville
- 102 Total Eye Care, PA - Memphis
Virginia
- 108 Emerson Clinical Research Institute Inc. - Falls Church
- 107 Virginia Eye Institute - Richmond
Kentucky
- 104 Butchertown Clinical Trials - Louisville
Massachusetts
- 101 Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05591755
The ClinicalTrials.gov registry entry for NCT05591755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Allergic Conjunctivitis appearing as the primary indexed condition, and to 4 interventions - of which Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution is the first listed.
NCT05591755 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, Virginia, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05591755 about?
NCT05591755 is a clinical study titled "Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis". To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.
What is the current status of trial NCT05591755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 229 participants. The study started on 2022-11-18. Estimated completion is 2023-08-09.
What conditions does trial NCT05591755 study?
This clinical trial studies the following conditions: Seasonal Allergic Conjunctivitis.
What interventions are being tested in trial NCT05591755?
The interventions under investigation include: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (DRUG), Ketotifen fumarate ophthalmic solution 0.035% (DRUG), Brimonidine tartrate ophthalmic solution 0.025% (DRUG), Experimental: Vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05591755?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05591755 being conducted?
This trial has 6 study locations across Kentucky, Massachusetts, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.